Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.58 |
| ▸ | ITGA5 | P08648 | 9/20 | 0.58 |
| ▸ | ITGAV | P06756 | 6/20 | 0.45 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.41 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455400 | 1.00 | ITGB1 (0.58) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL23978757 | 0.93 | ITGB1 (0.51) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL23489201 | 0.92 | ITGB1 (0.50) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL23455429 | 0.92 | ITGB1 (0.50) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL23489252 | 0.91 | ITGB1 (0.49) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL23978867 | 0.89 | ITGB1 (0.47) | ITGB1ITGA5ITGAVKDM4EMEN1 | |
| SCHEMBL28884242 | 0.88 | ITGB1 (0.45) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL28884210 | 0.87 | ITGB1 (0.73) | ITGB1ITGA5ITGAVITGB8MEN1 | |
| SCHEMBL24805471 | 0.86 | ITGB1 (0.46) | ITGB1ITGA5ITGAVITGB8KDM4E | |
| SCHEMBL23455520 | 0.85 | ITGB1 (0.51) | ITGB1ITGA5ITGAVITGB8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| EP-4142707-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| CN-115348861-A | Alpha-5 beta-1 inhibitors | 加利福尼亚大学董事会 | 2022-11-15 | — | — | CN | disclosed |
| EP-4072541-A1 | ALPHA-5 BETA-1 INHIBITORS | The Regents of the University of California (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | ITGB1 1/4885ITGA5 15/4885ITGAV 10/4885 |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | ITGB1 138/4885ITGA5 19/4885ITGAV 1756/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | ITGB1 1/4885ITGA5 15/4885ITGAV 10/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | ITGB1 138/4885ITGA5 19/4885ITGAV 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.